一分钟看懂
这是一项关于晚期实体瘤的I 期研究，登记的药物或干预包括BG-C0979；Tislelizumab，当前状态为招募中。登记地点显示中国北京、重庆、福州、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BG-C0979；Tislelizumab · I 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录6项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出3项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Cancer Hospital Chinese Academy of Medical Sciences · 北京
- Second Affiliated Hospital of Army Medical University (Xinqiao Hospital) · 重庆
- Mengchao Hepatobiliary Hospital of Fujian Medical University · 福州
- Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South) · 广州
- Yichang Central Peoples Hospital · 宜昌
- Fudan University Shanghai Cancer Centerpudong · 上海
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Phase 1a (Monotherapy Dose Escalation and Safety Expansion): Participants with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have previously received standard systemic therapy or for whom treatment is not available or not tolerated, or determined not appropriate based on investigator's judgment.
- * Phase 1b Part A (Monotherapy Dose Optimization and Expansion): Participants with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have previously received standard systemic therapy or for whom treatment is not available or not tolerated, or determined not appropriate based on investigator's judgment.
- * Phase 1b Part B (Combination Therapy Expansion): Participants with histologically or cytologically confirmed metastatic or unresectable advanced solid tumors who have not received any prior systemic treatment for advanced or metastatic disease.
- * Participants must have ≥ 1 measurable lesion as assessed by RECIST v1.1.
- * Participants must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- * Participants must have adequate organ function.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07414836；登记信息更新于 2026-09-28；本站同步于 2026-10-08。